📰 Genentech News
Page 175 - Genentech News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Genentech. Real-time updates on events, politics, business and more.
April 19, 2023
– Polivy combination is the first FDA-approved therapy in nearly 20 years for the first-line treatment of diffuse large B-cell lymphoma, an aggressive disease and the most common form of... | April 19, 2023
April 19, 2023
The Food and Drug Administration approved Polivy plus Rituxan, cyclophosphamide, doxorubicin and prednisone for patients with previously untreated diffuse large B-cell lymphoma — marking the first new regimen in nearly two decades for this patient population.
April 19, 2023
From May to September 2023, the Foundation’s Destination Healthy Skin RV will visit 30 communities around the U.S.
April 19, 2023
The obituary for Leslie Jay Schroeder, who worked for Pacific Bell for many years before taking a number of other interesting jobs, including a stint in Berlin for Fujitsu. He was also an avid cyclist.
April 19, 2023
Polivy combination is the first FDA-approved therapy in nearly 20 years for the first-line treatment of diffuse large B-cell lymphoma, an aggressive disease and the most common form of non-Hodgkin... | June 19, 2023
April 19, 2023
19.04.2023 - Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Polivy (polatuzumab vedotin-piiq) in combination with Rituxan (rituximab), cyclophosphamide, ...
April 18, 2023
/PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that leaders from Bristol Myers Squibb, Eli Lilly and Company, Genentech, Janssen, and Merck will be...
April 18, 2023
Moderna and Merck & Co. have presented positive mid-stage data at the American Association for Cancer Research (AACR) Annual Meeting 2023 for the combination of their personalized cancer vaccine (PCV) candidate and Merck’s blockbuster cancer immunotherapy Keytruda® (pembrolizumab).
April 18, 2023
The results showed median overall survival greater than 25 months and 6.3 months median progression free survival in PD-L1+ patientsVB10.16 was safe and well tolerated in combination with... | April 18, 2023
April 18, 2023
Lineage Cell Therapeutics, Inc. , a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that Brian M. Culley, Lineage’s Chief... | April 18, 2023